Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 switch study of Juluca in virologically suppressed children with HIV-1
2022-000829-24Phase 2
- Sponsor
- ViiV Healthcare
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dolutegravir + rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Steady-state AUC0-24h of dolutegravir through 24 weeks and Steady-state AUC0-24h of rilpivirine through 24 weeks.
02
Drugs
dolutegravir + rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-000829-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000829-24.